Breaking News

FDA Gives First Approval to Pre-Surgical Breast Cancer Drug
Download PDF
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...

On Monday, the FDA gave its first approval to a pre-surgical breast cancer drug. The drug, Perjeta, manufactured by Roche had been previously approved for late-stage breast cancer last year. Accelerated approval of the drug for treating pre-surgical breast cancer was given following a recent study that showed women who received the drug as an initial treatment were more likely to be free of cancer within 12 weeks earlier than those receiving prevalent drug combinations for treating breast cancer.

In early September, FDA scientists had positively reviewed the drug a few days before a panel of independent cancer specialists reviewed the benefits of Perjeta against risks of its use. The external panel voted 13-0 and the panel chairman, Dr. Mikkal Sekeres called the vote “a historic moment.”

  
What
Where


Earlier in September, CBS News contributor Dr. David Agus, of the Westside Cancer Center at the University of Southern California said on CBS This Morning that Perjeta was “an exciting drug because it targets a particular pathway in the cancer – an ‘on’ switch if you will. About 15,000 women a year have this very aggressive cancer with … (a molecule called HER-2) and it turns it off.”

The FDA based its approval on a 417-woman study that compared Perjeta in different combinations against prevalent drug combinations for breast cancer. When combined with Herceptin and standard chemotherapy, the cancer went down to undetectable levels in 39 percent of the women.

Perjeta is not a blanket treatment for all kinds of breast cancer, but is targeted towards breast cancer that is triggered by the protein HER-2.

Get JD Journal in Your Mail

Subscribe to our FREE daily news alerts and get the latest updates on the most happening events in the legal, business, and celebrity world. You also get your daily dose of humor and entertainment!!




Dr. Richard Pazdur, the director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, after approving Perjeta for pre-surgical breast cancer treatment, said, “We are seeing a significant shift in the treatment paradigm for early stage breast cancer … By making effective therapies available to high-risk patients in the earliest disease setting, we may delay or prevent cancer recurrences.”





 

RELEVANT JOBS

National Firm seeks seasoned Corporate M&A partner in Austin with Big Law experience

USA-TX-Austin

Culhane Meadows PLLC, one of the largest non-traditional (remote-workplace) law firms in the country...

Apply now

National Firm seeks seasoned Corporate M&A partner in Houston with Big Law experience

USA-TX-Houston

Culhane Meadows PLLC, one of the largest non-traditional (remote-workplace) law firms in the country...

Apply now

National Firm seeks seasoned Corporate M&A partner in Dallas with Big Law experience

USA-TX-Dallas

Culhane Meadows PLLC, one of the largest non-traditional (remote-workplace) law firms in the country...

Apply now

Trusts and Estates Paralegal

USA-PA-Philadelphia

We are looking for a paralegal with a 4-year degree and paralegal certificate, or equivalent experie...

Apply now

BCG FEATURED JOB

Locations:

Keyword:



Search Now

Junior Litigation Associate Attorney

USA-CA-Beverly Hills

Beverly Hills office of our client seeks junior associate attorney with 1-2 years of experience in l...

Apply Now

Immigration Attorney

USA-CA-Oakland

Oakland office of our client seeks immigration attorney with 3-5 years of experience. The candidate ...

Apply Now

Litigation Associate Attorney

USA-TX-Fort Worth

Fort Worth office of our client seeks litigation associate attorney with 3-6 years of experience. Th...

Apply Now

Most Popular

SEARCH IN ARCHIVE

To Top